Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Joaquin Bellmunt Molins, M.D.

Co-Author

This page shows the publications co-authored by Joaquin Bellmunt Molins and Toni Choueiri.
Connection Strength

11.219
  1. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014 Aug; 12(4):262-9.
    View in: PubMed
    Score: 0.586
  2. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013 Jun; 24(6):1466-72.
    View in: PubMed
    Score: 0.545
  3. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010 May 01; 28(13):2280-5.
    View in: PubMed
    Score: 0.446
  4. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol. 2009 Oct; 56(4):606-8.
    View in: PubMed
    Score: 0.425
  5. Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol. 2009 Aug; 10(8):740.
    View in: PubMed
    Score: 0.424
  6. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019 06 01; 30(6):970-976.
    View in: PubMed
    Score: 0.210
  7. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018 09; 119(6):707-712.
    View in: PubMed
    Score: 0.200
  8. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
    View in: PubMed
    Score: 0.196
  9. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 05; 118(11):1434-1441.
    View in: PubMed
    Score: 0.196
  10. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e961-e967.
    View in: PubMed
    Score: 0.194
  11. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018 01 22; 6(1):5.
    View in: PubMed
    Score: 0.192
  12. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Dec; 120:120-126.
    View in: PubMed
    Score: 0.189
  13. Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. Clin Genitourin Cancer. 2017 12; 15(6):e1089-e1094.
    View in: PubMed
    Score: 0.185
  14. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017 10; 198(4):817-823.
    View in: PubMed
    Score: 0.182
  15. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318.
    View in: PubMed
    Score: 0.180
  16. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292.
    View in: PubMed
    Score: 0.180
  17. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 03 16; 376(11):1015-1026.
    View in: PubMed
    Score: 0.180
  18. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
    View in: PubMed
    Score: 0.172
  19. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
    View in: PubMed
    Score: 0.172
  20. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 06 10; 6:27702.
    View in: PubMed
    Score: 0.171
  21. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
    View in: PubMed
    Score: 0.171
  22. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):494-498.
    View in: PubMed
    Score: 0.170
  23. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):352-9.
    View in: PubMed
    Score: 0.166
  24. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2016 Jan; 4(1):12-7.
    View in: PubMed
    Score: 0.165
  25. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016 Feb; 195(2):277-82.
    View in: PubMed
    Score: 0.162
  26. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):634-641.
    View in: PubMed
    Score: 0.162
  27. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS One. 2015; 10(6):e0124711.
    View in: PubMed
    Score: 0.160
  28. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Jun; 4(6):844-52.
    View in: PubMed
    Score: 0.157
  29. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
    View in: PubMed
    Score: 0.156
  30. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817.
    View in: PubMed
    Score: 0.155
  31. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. J Clin Oncol. 2014 Dec 20; 32(36):4171-2.
    View in: PubMed
    Score: 0.153
  32. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer. 2015 Jun; 13(3):250-6.
    View in: PubMed
    Score: 0.153
  33. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr; 13(2):185-92.
    View in: PubMed
    Score: 0.152
  34. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2178-2184.
    View in: PubMed
    Score: 0.152
  35. Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014; 9(8):e103325.
    View in: PubMed
    Score: 0.151
  36. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32.
    View in: PubMed
    Score: 0.149
  37. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.148
  38. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014 Sep; 66(3):529-41.
    View in: PubMed
    Score: 0.147
  39. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer. 2013 Nov 12; 109(10):2548-53.
    View in: PubMed
    Score: 0.142
  40. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014 Jul; 66(1):42-54.
    View in: PubMed
    Score: 0.141
  41. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013 Jul; 87(1):80-9.
    View in: PubMed
    Score: 0.135
  42. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
    View in: PubMed
    Score: 0.134
  43. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug; 14(4):295-306.
    View in: PubMed
    Score: 0.131
  44. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012 Jul; 48(10):1495-502.
    View in: PubMed
    Score: 0.125
  45. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011 Oct; 60(4):684-90.
    View in: PubMed
    Score: 0.121
  46. Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. J Clin Oncol. 2011 May 20; 29(15_suppl):4570.
    View in: PubMed
    Score: 0.121
  47. Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
    View in: PubMed
    Score: 0.121
  48. Identification of ALK gene alterations in urothelial carcinoma (UC). J Clin Oncol. 2011 May 20; 29(15_suppl):4568.
    View in: PubMed
    Score: 0.121
  49. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opin Drug Saf. 2011 Jul; 10(4):645-53.
    View in: PubMed
    Score: 0.120
  50. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Ann Oncol. 2011 Feb; 22(2):245-7.
    View in: PubMed
    Score: 0.118
  51. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
    View in: PubMed
    Score: 0.118
  52. ¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. BJU Int. 2010 Nov; 106(9):1249-50.
    View in: PubMed
    Score: 0.116
  53. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010 Apr 10; 28(11):1850-5.
    View in: PubMed
    Score: 0.111
  54. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470.
    View in: PubMed
    Score: 0.051
  55. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.050
  56. Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018 06; 19(6):e317-e326.
    View in: PubMed
    Score: 0.049
  57. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 05; 1(1):83-90.
    View in: PubMed
    Score: 0.049
  58. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018 06 01; 36(16):1579-1587.
    View in: PubMed
    Score: 0.048
  59. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.048
  60. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
    View in: PubMed
    Score: 0.048
  61. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
    View in: PubMed
    Score: 0.047
  62. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382.
    View in: PubMed
    Score: 0.046
  63. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017 Oct 13; 8(48):84572-84578.
    View in: PubMed
    Score: 0.046
  64. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017 Nov 15; 123(22):4346-4355.
    View in: PubMed
    Score: 0.046
  65. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.045
  66. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
    View in: PubMed
    Score: 0.045
  67. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017 Feb; 53:79-97.
    View in: PubMed
    Score: 0.044
  68. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2017 05; 71(5):714-718.
    View in: PubMed
    Score: 0.044
  69. Prog Urol. 2016 Nov; 26(13):674-675.
    View in: PubMed
    Score: 0.044
  70. Prog Urol. 2016 Nov; 26(13):676-677.
    View in: PubMed
    Score: 0.044
  71. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.044
  72. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
    View in: PubMed
    Score: 0.042
  73. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
    View in: PubMed
    Score: 0.041
  74. Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
    View in: PubMed
    Score: 0.041
  75. Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):361-76, x.
    View in: PubMed
    Score: 0.039
  76. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):395-8.
    View in: PubMed
    Score: 0.037
  77. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb; 13(1):71-9.
    View in: PubMed
    Score: 0.037
  78. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44.
    View in: PubMed
    Score: 0.037
  79. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
    View in: PubMed
    Score: 0.037
  80. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
    View in: PubMed
    Score: 0.036
  81. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):130-7.
    View in: PubMed
    Score: 0.036
  82. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013 Dec; 11(4):495-500.
    View in: PubMed
    Score: 0.035
  83. Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):301.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.